Table 1.
RICs
| Antibody | Target | Isotope | Indication | Stage of development |
|---|---|---|---|---|
| Anti-Tac antibody (90Y-HAT) | CD25 | 90Y | T-cell NHL, HL | Phase 1 NCT00001575 |
| BB4 antibody | CD138 | 131I | MM | Phase 1 NCT01296204 |
| BC8 antibody-streptavidin conjugate | CD45 | 131I, 90Y | AML, ALL, MDS | Phase 1 NCT00988715 |
| Daclizumab (CHX-A daclizumab) | CD25 | 90Y | HL | Phase 1/2 NCT01468311 |
| Epratuzumab | CD22 | 90Y | B-cell NHL, WM | Phase 1/2 NCT01101581, NCT00004107 |
| Ibritumomab tiuxetan | CD20 | 90Y | B-cell NHL | Approved 2002 |
| Lintuzumab | CD33 | 225Ac | AML | Phase 1/2 NCT01756677 |
| Tositumomab | CD20 | 131I | B-cell NHL | Approved 2003; to be discontinued February 2014 |
HAT, humanized anti-Tac; WM, Waldenstrom macroglobulinemia.